January 14, 2016: Vaccines and Related Biological Products Advisory Committee Meeting Draft Agenda
Food and Drug Administration
Center for Biologics Evaluation and Research (CBER)
January 14, 2016
141st Vaccines and Related Biological Products Advisory Committee Meeting
Via Teleconference
Office of Vaccines Research and Review (OVRR)
Division of Viral Products (DVP)
Laboratory of Method Development (LMD)
Building 31, Great Room, Salon A
Silver Spring, MD
Live Webcast: https://collaboration.fda.gov/vrbpacsem1/
Time | Presentation/Presenter |
---|---|
Open Session | |
1:00 p.m. | Call to Order and Opening Remarks Robert Daum, M.D., Chair |
Conflicts of Interest Statement Sujata Vijh, Ph.D., DFO |
|
Topic: Presentations of the Laboratory of Method Development, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research | |
1:15 p.m. | Overview of CBER Research/Site Visit Process Carolyn Wilson, Ph.D. Associate Director for Research CBER, FDA |
1:35 p.m. | Overview of OVRR Konstantin Chumakov, Ph.D. Associate Director for Research OVRR, CBER, FDA |
1:50 p.m. | Overview of DVP Jerry Weir, Ph.D. Director DVP, CBER, FDA |
2:00 p.m. | Overview of LMD Steven Rubin, Ph.D. Acting Laboratory Chief LMD, DVP, CBER, FDA |
2:30 p.m. | Questions |
2:35 p.m. | Open Public Hearing (if no speakers, will move directly to closed session) |
3:35 p.m. | Closed Session |
5:00 p.m. | Adjournment |